Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRX2 is a molecular food supplement (nutraceutical) developed by Oxford Biolabs Ltd. for the management of hair loss and thinning. The product was formulated based on research into the role of potassium channels in hair follicles, specifically the hypothesis that impaired potassium channel function contributes to hair follicle miniaturization in androgenetic alopecia. TRX2 contains a proprietary combination of L-carnitine-L-tartrate, potassium chloride, branched-chain amino acids (L-leucine, L-isoleucine, and L-valine), nicotinamide, and biotin. The supplement is intended to support the maintenance of normal hair by facilitating the transport of nutrients into the hair follicle and stimulating hair follicle metabolism. It is marketed as a non-pharmaceutical, drug-free alternative to traditional hair loss treatments like minoxidil or finasteride.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TRX2.